Inna Serganova
Overview
Explore the profile of Inna Serganova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
2018
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verma S, Budhu S, Serganova I, Dong L, Mangarin L, Khan J, et al.
J Clin Invest
. 2024 Sep;
134(17).
PMID: 39225102
Tumor reliance on glycolysis is a hallmark of cancer. Immunotherapy is more effective in controlling glycolysis-low tumors lacking lactate dehydrogenase (LDH) due to reduced tumor lactate efflux and enhanced glucose...
2.
Schreier A, Zappasodi R, Serganova I, Brown K, Demaria S, Andreopoulou E
Front Oncol
. 2023 Jan;
12:1061789.
PMID: 36703796
Triple negative breast cancer (TNBC) is an aggressive disease that is difficult to treat and portends a poor prognosis in many patients. Recent efforts to implement immune checkpoint inhibitors into...
3.
Maeda M, Ko M, Mane M, Cohen I, Shindo M, Vemuri K, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565435
The effects of the LDH-A depletion via shRNA knockdown on three murine glioma cell lines and corresponding intracranial (i.c.) tumors were studied and compared to pharmacologic (GNE-R-140) inhibition of the...
4.
Shindo M, Maeda M, Myat K, Mane M, Cohen I, Vemuri K, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565432
Three murine glioma cell lines (GL261, CT2A, and ALTS1C1) were modified to downregulate the expression of the murine gene using shRNA, and compared to shRNA scrambled control (NC) cell lines....
5.
Serganova I, Chakraborty S, Yamshon S, Isshiki Y, Bucktrout R, Melnick A, et al.
Front Cell Dev Biol
. 2022 Jan;
9:805195.
PMID: 35071240
B-cell non-Hodgkin lymphomas (B-NHLs) are highly heterogenous by genetic, phenotypic, and clinical appearance. Next-generation sequencing technologies and multi-dimensional data analyses have further refined the way these diseases can be more...
6.
Introducing a new reporter gene, membrane-anchored luciferase, for multiplex bioluminescence imaging
Moroz M, Zurita J, Moroz A, Nikolov E, Likar Y, Dobrenkov K, et al.
Mol Ther Oncolytics
. 2021 Apr;
21:15-22.
PMID: 33851009
Bioluminescence reporter gene imaging is a robust, high-throughput imaging modality that is useful for tracking cells and monitoring biological processes, both in cell culture and in small animals. We introduced...
7.
Zappasodi R, Serganova I, Cohen I, Maeda M, Shindo M, Senbabaoglu Y, et al.
Nature
. 2021 Feb;
591(7851):652-658.
PMID: 33588426
Limiting metabolic competition in the tumour microenvironment may increase the effectiveness of immunotherapy. Owing to its crucial role in the glucose metabolism of activated T cells, CD28 signalling has been...
8.
Mane M, Cohen I, Ackerstaff E, Shalaby K, Ijoma J, Ko M, et al.
Mol Ther Oncolytics
. 2020 Sep;
18:382-395.
PMID: 32913888
To enhance human prostate-specific membrane antigen (hPSMA)-specific chimeric antigen receptor (CAR) T cell therapy in a hPSMA MyC-CaP tumor model, we studied and imaged the effect of lactate dehydrogenase A...
9.
Serganova I, Blasberg R
J Nucl Med
. 2019 Dec;
60(12):1665-1681.
PMID: 31792128
The first reporter systems were developed in the early 1980s and were based on measuring the activity of an enzyme-as a surrogate measure of promoter-driven transcriptional activity-which is now known...
10.
Serganova I, Cohen I, Vemuri K, Shindo M, Maeda M, Mane M, et al.
PLoS One
. 2018 Sep;
13(9):e0203965.
PMID: 30248111
Previous studies show that LDH-A knockdown reduces orthotopic 4T1 breast tumor lactate and delays tumor growth and the development of metastases in nude mice. Here, we report significant changes in...